India caps cancer drug margins, cutting 1,364 formulation prices

India's National Pharmaceutical Pricing Authority has capped trade margins on 137 anti-cancer drugs, and revised maximum retail prices for 1,364 formulations took effect on Monday, with 679 brands cutting prices by more than half.

Why it matters: The margin cap is India's widest single repricing of cancer medicines, and the pricing authority estimates it will save consumers about 3,540 crore rupees a year on drugs whose trade margins had long been a target of Indian health policy.

Data as of Press Information Bureau release of November 9, 2026 (11:51 a.m. IST, in Hindi), read in full in this run; every figure comes from the release itself, issued for the Department of Pharmaceuticals. Developing item.

India’s National Pharmaceutical Pricing Authority has capped the trade margin on the maximum retail price of 137 anti-cancer drugs, acting on the recommendations of an expert committee set up on October 17 by the Directorate General of Health Services. The revised prices took effect on Monday, November 9.

As of November 8, 85 pharmaceutical companies had reported revised maximum retail prices for 1,364 anti-cancer formulations covering 121 of the drugs. Of those, 679 brands cut prices by more than 50 percent, and the largest single reduction was 96.45 percent. The pricing authority estimates the cuts will save consumers about 3,540.38 crore rupees a year, and says no chemist or hospital pharmacy may charge above the revised price printed on the pack.

India caps cancer drug margins, cutting 1,364 formulation prices

Sources